Standout Papers

Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza 2020 2026 2022 2024360
  1. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza (2020)
    Timothy R. Abbott, Girija Dhamdhere et al. Cell

Immediate Impact

3 by Nobel laureates 6 from Science/Nature 60 standout
Sub-graph 1 of 23

Citing Papers

Amplification-free, OR-gated CRISPR-Cascade reaction for pathogen detection in blood samples
2025 Standout
Past, present, and future of CRISPR genome editing technologies
2024 Standout
2 intermediate papers

Works of Girija Dhamdhere being referenced

Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza
2020 Standout

Author Peers

Author Last Decade Papers Cites
Girija Dhamdhere 473 60 65 175 129 11 790
Kyung–Hee Choi 350 111 14 85 85 24 885
Ijad Madisch 191 60 21 300 489 14 833
Minako Ohishi 434 35 31 104 183 13 911
Josefine Hirschfeld 233 50 8 82 65 32 979
Jochen Decker 411 123 37 49 122 22 840
Jixin Cui 554 34 23 53 129 10 950
Stefan A. Hienz 329 65 8 153 26 11 890
Max M. Villa 238 66 13 57 35 13 669
Fatiha Chellat 334 68 71 16 92 10 856
Tatsuya Shibata 448 98 5 104 165 41 957

All Works

Loading papers...

Rankless by CCL
2026